IQVIA Holdings Chairman and CEO Ari Bousbib sold about 106,000 shares for total proceeds of $26.1 million, according to an SEC filing. The transaction was an exercise-and-sell of stock appreciation rights expiring in February 2027, with shares sold at a weighted average price of $245.51, a narrow discount to the July 29 market close of $247.56. Bousbib retains a total beneficial position of 1.4 million shares, including 543,000 shares held indirectly through the Orohena Trust. The sale followed a standout quarter in which IQVIA reported second-quarter revenue of $4.37 billion, a 12.1% increase in adjusted earnings per share to $3.15, and record clinical bookings of $3.15 billion, while raising full-year guidance to as much as $17.475 billion.
IQVIA Holdings IncRecord bookings and raised guidance are positive, while CEO sale is minor.